CompoAtlas

Electrolyte

Electrolyte, licence 80145794: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names
Electrolyte Balance, Electrolyte Plus
Licence holder
WN Pharmaceuticals Ltd
NPN or DIN-HM
80145794
Status
Active licence
Licence date
1 December 2025
Revision date
10 July 2026
Form
Poudre
Route of administration
Orale
Application type
Générale (non traditionelle)

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Phosphore35.0 mgNot calculated
Calcium75.0 mgNot calculated
Cocos nucifera100.0 mgNot calculated

Non-medicinal ingredients

Citrate de sodium dihydraté, Acide citrique, Saveur, Chlorure de sodium, Sel de mer, Extrait purifié de feuilles de stévia, Acide L-malique, Bicarbonate de sodium

PopulationAgeQuantity per servingFrequency
Adultesminimum: 19.0 Année(s)minimum: 1.0 Portions ; maximum: 2.0 Portions1.0 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may help prevent bone loss/osteoporosis (in peri- and postmenopausal women) (in later life). Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may reduce the risk of developing osteoporosis (in peri- and postmenopausal women) (in later life). As part of a healthy diet (when taken with Vitamin D) may help prevent bone loss/osteoporosis. Helps in bone development. Helps in energy metabolism/(and) tissue formation. Helps in the development and maintenance of bones/(and) teeth. Helps maintain/support bone health. Helps to maintain/support heart muscle function. Helps to maintain/support normal electrolyte balance. Helps to maintain/support normal muscle function, including the heart muscle. Helps to maintain/support normal muscle function. Helps to maintain/support the body's ability to metabolize nutrients. Source of/Provides (an) electrolyte(s) for the maintenance of good health. Source of/Provides (an) electrolyte(s). Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Source of (an) antioxidant(s)/Provides (an) antioxidant(s).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80145794

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line